Reviewing Acorda Therapeutics Inc. (ACOR)’s and Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR)’s results – MS Wkly

Posted: Published on November 6th, 2019

This post was added by Alex Diaz-Granados

Both Acorda Therapeutics Inc. (NASDAQ:ACOR) and Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) are each others competitor in the Biotechnology industry. Thus the contrast of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

Table 1 showcases the top-line revenue, earnings per share and valuation of Acorda Therapeutics Inc. and Eiger BioPharmaceuticals Inc.

Profitability

Table 2 provides Acorda Therapeutics Inc. and Eiger BioPharmaceuticals Inc.s return on equity, net margins and return on assets.

Volatility & Risk

A 1.1 beta means Acorda Therapeutics Inc.s volatility is 10.00% more than S&P 500s volatility. Eiger BioPharmaceuticals Inc. on the other hand, has 0.99 beta which makes it 1.00% less volatile compared to S&P 500.

Liquidity

The Current Ratio of Acorda Therapeutics Inc. is 4.3 while its Quick Ratio stands at 4. The Current Ratio of rival Eiger BioPharmaceuticals Inc. is 8.2 and its Quick Ratio is has 8.2. Eiger BioPharmaceuticals Inc. is better equipped to clear short and long-term obligations than Acorda Therapeutics Inc.

Analyst Ratings

Acorda Therapeutics Inc. and Eiger BioPharmaceuticals Inc. Ratings and Recommendations are available in the next table.

The consensus target price of Acorda Therapeutics Inc. is $8.88, with potential upside of 269.58%.

Institutional & Insider Ownership

Institutional investors held 0% of Acorda Therapeutics Inc. shares and 76.2% of Eiger BioPharmaceuticals Inc. shares. Insiders held roughly 1.5% of Acorda Therapeutics Inc.s shares. Comparatively, insiders own roughly 0.4% of Eiger BioPharmaceuticals Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Acorda Therapeutics Inc. had bearish trend while Eiger BioPharmaceuticals Inc. had bullish trend.

Summary

Acorda Therapeutics Inc. beats on 7 of the 11 factors Eiger BioPharmaceuticals Inc.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinsons disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinsons disease; SYN120, which is in Phase II clinical trial to treat Parkinsons disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Womens Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View post:
Reviewing Acorda Therapeutics Inc. (ACOR)'s and Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR)'s results - MS Wkly

Related Posts
This entry was posted in Spinal Cord Injury Treatment. Bookmark the permalink.

Comments are closed.